This article is more than 5 years old. Information may no longer be current.

Hybridon licenses VEGF patents

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CAMBRIDGE, Mass. — Hybridon, a company that specializes in therapies based on synthetic DNA, has licensed its patents on the use of vascular endothelial growth factor for ocular indications with RNA interference molecules to biotech firm Alnylam Pharmaceuticals, the companies announced in a press release. The VEGF protein has been associated with macular degeneration, the companies said.

Hybridon will continue to “pursue the studies of antisense-based compounds targeting VEGF for ocular diseases,” the release said.

RNA interference (RNAi) occurs naturally and can selectively silence and regulate specific genes, according to Alnylam. Researchers believe RNAi may be the foundation of a new class of therapeutic drugs, according to the press release.